{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262945522443904.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00535-009-0024-z"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-009-0024-z.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00535-009-0024-z/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-009-0024-z"}},{"identifier":{"@type":"PMID","@value":"19308310"}}],"dc:title":[{"@value":"Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection"}],"description":[{"notation":[{"@value":"In patients chronically infected with hepatitis B virus, interferon has been used for the purpose of viral suppression by loss of hepatitis B e antigen (HBeAg) with or without seroconversion to antibody to HBeAg (anti-HBe). However, discussion about the effect of interferon on the development of hepatocellular carcinoma (HCC) has been controversial.We conducted a meta-analysis of published studies. Eight studies were retrieved (1,303 patients), including two randomized controlled trials (RCTs) and six non-RCTs (553 patients received interferon treatment).The pooled estimate of the preventive effect of treatment was significantly in favor of interferon (risk difference -5.0%; 95% CI -9.4 to -0.5, P = 0.028). By subgroup analyses, the preventive effect of interferon treatment was shown in the Asian population (risk difference -8.5%; 95%CI -13.6 to -3.6, P = 0.0012), the population with the incidental rate of HCCor=10% if untreated with interferon (risk difference -9.4%; 95%CI -14.2 to -4.6, P = 0.0001), and the population with the proportion of HBeAg-positive patients to the study populationor=70% (RD -6.0%; 95%CI -11.8 to -0.2, P = 0.043). However, the preventive effect of interferon was not shown in the European population, the population with a lower incidental rate of HCC if untreated with interferon, and the population with the lower proportion of HBeAg-positive patients to the study population. An evaluation using the Begg method indicated no evidence of publication bias.Interferon treatment is considered to restrain HCC development in patients with chronic hepatitis B virus infection, especially in HBeAg-positive Asians."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262945522443904","@type":"Researcher","foaf:name":[{"@value":"Yasuhiro Miyake"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945522443906","@type":"Researcher","foaf:name":[{"@value":"Haruhiko Kobashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262945522443905","@type":"Researcher","foaf:name":[{"@value":"Kazuhide Yamamoto"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09441174"},{"@type":"EISSN","@value":"14355922"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2009-03-25","prism:volume":"44","prism:number":"5","prism:startingPage":"470","prism:endingPage":"475"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-009-0024-z.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00535-009-0024-z/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-009-0024-z"}],"createdAt":"2009-03-24","modifiedAt":"2019-05-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Carcinoma,%20Hepatocellular","dc:title":"Carcinoma, Hepatocellular"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Liver%20Neoplasms","dc:title":"Liver Neoplasms"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Interferons","dc:title":"Interferons"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664562973056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664563272064","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206447135488","@type":"Article","resourceType":"other","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7. Cutting Edge of the Treatment for Viral Hepatitis"},{"@language":"ja","@value":"7．ウイルス性肝炎の治療の進歩"},{"@value":"教育講演 ウイルス性肝炎の治療の進歩"},{"@language":"ja-Kana","@value":"キョウイク コウエン ウイルスセイ カンエン ノ チリョウ ノ シンポ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-009-0024-z"},{"@type":"OPENAIRE","@value":"doi_dedup___::c6e1196e0224a5e8da30b52fc0339849"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"},{"@type":"CROSSREF","@value":"10.3748/wjg.v21.i27.8249_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"},{"@type":"CROSSREF","@value":"10.3748/wjg.v22.i32.7252_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"},{"@type":"CROSSREF","@value":"10.2169/naika.101.2681_references_DOI_HaAh235t2sq9nUErT8vhViEx2j"}]}